News

An analysis of data from the phase 4 MOSAIC trail is providing clinicians with a greater understanding of the effects of apremilast in people with uncontrolled psoriatic arthritis.

An analysis of 100 week data from the KEEPsAKE 1 and 2 trials presented at EULAR 2023 offers insight into the long-term effects of risankizumab use in people with psoriatic arthritis.

An analysis of patient-reported outcomes data from the MIRROR trial offers insight into the effects of pegloticase plus methotrexate on quality of life and various disease activity indices.

New data from EULAR 2023 offers a comparison of the levels of vascular inflammation among patients with psoriatic arthritis relative to healthy controls.

An analysis of patient data from Sweden and Norway detail the impact of achieving remission with methotrexate or TNF inhibitors on risk of acute coronary syndrome in patients with rheumatoid arthritis.

An analysis of NHANES data from 2011-2018 presented at EULAR 2023 offers an overview of the disproportionate growth in gout burden for Asian Americans relative to their White counterparts.

Data from the BE VITAL OLE study, which included patients from the BE COMPLETE and BE OPTIMAL studies, suggests the benefits of bimekizumab in patients with psoriatic arthritis with inadequate response or intolerance to TNF inhibitors were sustained for up to 52 weeis.

The disparities compelled them to launch Determi-Nation, which utilizes healthcare providers, advocates, and patients within the psoriatic disease community to co-create solutions that address the observed inequities.

An analysis of data from more than 60,000 postmenopausal women within the Women's Health Initiative has returned results indicating the guideline-recommended FRAX score may be insufficient for making screening decisions.

Patients with higher platelet or neutrophil counts or platelet/lymphocyte ratios and systemic immune/inflammation index scores were more resistant to conventional systemic agents.

Statistically significant improvements were observed in all 10 PROMIS domains analyzed.

An analysis of patient-reported outcomes data from more than 15,000 people with rheumatic disease sheds light on the apparent differences in impact on quality of life between psoriatic arthritis and rheumatoid arthritis.

The analyses emphasized the early and sustained resolution of enthesitis through 52 weeks with both adalimumab and secukinumab.

A fibromyalgia diagnosis was significantly associated with GERD, IBS, Crohn’s disease, ulcerative colitis, and celiac disease.

Significant improvements in pain intensity, health-related quality of life, and depression were observed in patients receiving an online pain management intervention.

At the 12-week mark, the change from baseline in the DAS28-CRP was significantly greater in patients with rheumatoid arthritis receiving 700 mg peresolimab when compared with the placebo group.

Leveraging data from the 2020 UPLIFT survey, investigators offer an overview of the quality of life and treatment satisfaction among people with psoriasis and psoriatic arthritis in the US.

At the 2-year mark after methotrexate initiation, 71% of patients with psoriatic arthritis and 76% of patients with rheumatoid arthritis remained on methotrexate.

Patients with fibromyalgia reported significantly less recreational, transportation-related, and total physical activity levels when compared with controls.

An analysis of the Clinical Practice Research Datalink provides an overview of trends and prevalence of long-term opioid use among patients with 1 of 6 rheumatic or musculoskeletal diseases using 3 definitions of long-term opioid use.

In addition to demonstrating efficacy, the numbers and incidence rates of treatment-emergent adverse events and treatment-emergent infections decreased throughout the 10-year follow-up.

Pooled results proved that telerehabilitation improved the Fibromyalgia Impact Questionnaire score and quality of life in patients with fibromyalgia when compared with controls.

Sustained low disease activity/remission was associated with functional and health-related quality of life improvements.

The findings suggest rural patients treated for gout had higher treatment adherence compared with urban patients.

A phase 3 trial comparing QL1206, a denosumab biosimilar, to the reference agent has returned results demonstrating the efficacy, safety, and pharmacokinetic equivalency of the biosimilar to the reference agent.

The long-term extension SENSCIS-ON trial shows patients receiving nintedanib over 3 years were not at significantly greater risk of serious adverse events or outcomes.

A study leveraging DoD data provides a comprehensive overview of clinical features, treatment choices, and outcomes of patients with immune mediated necrotizing myopathy relative to those of patients with other idiopathy inflammatory myopathies.

According to the study, these findings can inform policy decisions and assist in developing interventions aimed at reducing absenteeism and promoting the productivity of individuals with idiopathic inflammatory rheumatic diseases.

At the 12-month mark, 52% of patients in the axSpA cohort and 76% of those in the IBD cohort achieved clinical remission.